Biotech: Pesky pimple-like rosacea to get Botanix’s Permetrex treatment in early study

Botanix Pharmaceuticals (ASX:BOT) will try out its Permetrex drug delivery system in inflammatory rosacea patients after receiving ethics approval for a phase Ib study of two BTX 1702 formulations in its pipeline. The early-stage clinical study will target the pesky problem of papulopustular rosacea, a pimple-like rosacea that inflames skins that often affects women aged … Continue reading Biotech: Pesky pimple-like rosacea to get Botanix’s Permetrex treatment in early study

Stockhead

Hear it first

Get the latest Stockhead news delivered free to your inbox.

Email Lists

Thanks! You’re subscribed, Stockhead news is coming your way soon.